Filing identity and reporting period
Important identity mismatch: The supplied filing is AVROBIO, Inc.’s Form 10-Q, not a filing by Tectonic Therapeutic, Inc. It covers the quarter and nine months ended September 30, 2022, and was filed November 8, 2022. The summary below reflects AVROBIO’s filing.
AVROBIO is a clinical-stage gene therapy company developing hematopoietic stem cell gene therapies for rare diseases. It reported no product revenue.
Financial results and liquidity
Amounts below are in millions of dollars, except per-share data. The company had no revenue or gross margin; profitability and operating margins are not meaningful for this pre-commercial business.
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Research and development expense | $15.9 | $23.0 | $54.0 | $64.1 |
| General and administrative expense | $7.1 | $9.6 | $26.1 | $26.8 |
| Total operating expenses | $23.0 | $32.6 | $80.2 | $90.9 |
| Net loss | $23.0 | $32.6 | $80.9 | $90.9 |
| Basic and diluted net loss per share | $(0.52) | $(0.75) | $(1.85) | $(2.13) |
| Cash used in operating activities | — | — | $73.5 | $72.1 |
At September 30, 2022, cash and cash equivalents were $116.0 million, plus $0.5 million of restricted cash. Current assets were $126.2 million and current liabilities $16.2 million. The company reported $15.2 million of long-term note payable, net of discount; the funded principal was $15.0 million. It had no material revenue, and the filing does not present profit margins as an applicable performance measure.
Management estimated that cash on hand would fund operating expenses and capital expenditures into the first quarter of 2024, subject to assumptions that could prove wrong. The notes also state cash was expected to cover at least the 12 months following filing. Additional funding will be needed to support longer-term operations.
Changes versus comparable periods
- Q3 net loss narrowed by $9.6 million year over year; nine-month net loss narrowed by $10.0 million.
- Q3 R&D expense declined $7.1 million, primarily from lower personnel and manufacturing costs, partly offset by higher consulting costs. Nine-month R&D fell $10.1 million, mainly reflecting lower personnel and manufacturing costs, partly offset by consulting expense.
- Q3 G&A expense declined $2.5 million, primarily due to lower personnel, facility and professional costs. Nine-month G&A decreased $0.6 million.
- Nine-month operating cash use increased to $73.5 million from $72.1 million. Financing cash flow fell to $0.2 million from $15.4 million, as the prior-year period included $14.6 million of net ATM proceeds.
Outlook, management commentary and notable risks
- Pipeline priorities: AVROBIO deprioritized AVR-RD-01 for Fabry disease in January 2022 after variable engraftment data in recently dosed patients and concerns about an extended development timeline and the disease’s market and regulatory environment. Enrollment in the Phase 2 trial stopped. The decision also eliminated access to $20.0 million of milestone-contingent loan tranches.
- Active development: AVR-RD-02 for Gaucher disease was in a company-sponsored Phase 1/2 trial, with four patients dosed and six enrolled; updated interim data were planned for December 2022. AVR-RD-04 for cystinosis had six patients dosed in a collaborator-sponsored trial; the company planned a company-sponsored Phase 1/2 trial in the second half of 2023, subject to regulatory discussions. For AVR-RD-05, UK regulators accepted the collaborator’s trial application; first-patient dosing was expected in the first half of 2023.
- Delayed program: AVR-RD-03 for Pompe disease remained preclinical. The company no longer expected to start a clinical trial in 2023, while prioritizing Gaucher and cystinosis.
- Restructuring: A workforce reduction of approximately 23% followed the Fabry reprioritization. AVROBIO recorded $1.4 million in 2022 restructuring expense, all paid by September 30.
- Debt terms: The loan matures October 1, 2026, bears interest at the greater of prime plus 4.85% or 8.10%, and has interest-only payments through November 2024. It is secured by substantially all assets other than intellectual property and includes operating covenants and a 9% end-of-term charge on funded advances.
- Key risks: The company has a history of losses, no product sales, and expects continued significant spending. Clinical efficacy and safety, patient enrollment, manufacturing scale-up, reliance on sole-source suppliers, regulatory approval, access to further capital, and potential dilution remain material uncertainties. COVID-19-related disruption and gene-therapy safety risks are also discussed.
- Listing and controls: Nasdaq notified the company in October 2022 that its share price had not met the $1.00 minimum bid requirement. The stated deadline to regain compliance was April 3, 2023. Management reported disclosure controls were effective at the reasonable-assurance level and no material litigation was pending or threatened.
Investor verification priorities
- Confirm the issuer identity: this document is AVROBIO’s 10-Q, not Tectonic Therapeutic’s.
- Check subsequent clinical updates for the Gaucher, cystinosis and Hunter programs, including the planned timelines and trial status.
- Reassess cash runway against actual spending, trial costs, financing availability and management’s stated first-quarter 2024 estimate.
- Review loan covenants, interest and end-of-term costs, and the availability of any remaining borrowing tranches.
- Verify Nasdaq bid-price compliance and any subsequent listing or capital-raising actions.